EGFR and head and neck squamous cell carcinoma: Furthermore, we observed an additive to synergistic interaction between the EGFR inhibitor cetuximab and the pan-Akt inhibitor MK2206 in cetuximab sensitive and acquired cetuximab resistant HNSCC cell lines.